HPV Testing & Pap Test Market Size, Share, Competitive Landscape and Trend Analysis Report, by Test Type, by Application, by Location of Testing : Global Opportunity Analysis and Industry Forecast, 2021-2031

HPV Testing and Pap Test Market Research, 2031

The global HPV testing and Pap test market size was valued at $3.7 billion in 2021, and is projected to reach $6.7 billion by 2031, growing at a CAGR of 6.1% from 2022 to 2031. Human papillomavirus (HPV) is the most common sexually transmissible infection in world, belonging to papillomaviridae family. Human papillomavirus is a double stranded DNA tumor virus that causes epithelial proliferation at cutaneous and mucosal surfaces. Depending on the risk associated, HPV is categorized into two groups such as low-risk HPVs and high-risk HPVs. There are about 14 high-risk HPV types including HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. High-risk strains of HPV are now well established as the causative agents responsible for cervical and vaginal cancer. HPV 16 type is the most oncogenic, accounting for almost half of all cervical cancers, and HPV 16 and 18 together account for approximately 70% of cervical cancers.

Pap tests, HPV testing and co-test are included in cervical cancer screening which is a crucial part of a woman’s routine health checkup as it can diagnose abnormalities that could result in cancer of the cervix.  The human papillomavirus (HPV) test checks cells for infection with high-risk HPV types that can cause cervical cancer. The Pap test (also called a Pap smear or cervical cytology) collects cervical cells so they can be checked for changes caused by HPV that may - if left untreated - turn into cervical cancer. The HPV/Pap co-test uses an HPV test and Pap test together to check for both high-risk HPV and cervical cell changes. Furthermore, women belonging to 21 – 29 years of age, are suggested first Pap test at age 21 followed by Pap testing every 3 years and for women aged 30 – 65 years, are recommended HPV test every 5 years / co-test every 5 years / Pap test every 3 years.   

Historical Overview 

The HPV testing and Pap test market size was analyzed qualitatively and quantitatively from 2021-2031. The HPV testing and Pap test market grew at a CAGR of around 6.1% during 2021-2031. Most of the growth during this period was derived from the Asia-Pacific owing to the owing to factors such as effective screening programs for cervical and vaginal cancer, awareness regarding early screening for cervical cancer, and an increase in the prevalence of cervical cancer cases.    

Market Dynamics 

Growth & innovations in the pharmaceutical industry for the manufacturing of screening test kits owing to massive pool of health-conscious consumers, creates an HPV testing and Pap test market opportunity. Furthermore, increase in prevalence of cervical cancer cases across many regions, results in increase in demand for screening test for human papillomavirus, driving the growth of market. For instance, according to article published in American Scoiety of Clinical Oncology Journal 2021, stated that, Africa represents 20% of the world’s new cervical cancer cases every year accounting for approximately 120,000 new cases.  

Furthermore, rise in launch of various screening test kits, rise in new specific HPV type testing kit for cervical cancer screening by various key players across the globe are some HPV testing and Pap test market trends that drive growth of the market. For instance, in 2021, Roche received US Food and Drug Administration (FDA) approval for the cobas HPV test for use, which identifies women at risk for cervical cancer by detecting the presence of high-risk human papillomavirus (HPV) DNA in cervical samples.

However, changes in regulatory guidelines for cervical cancer screening restrain HPV testing and Pap test market growth. In addition, availability of human papillomavirus vaccination across the globe also might hinder the growth of market. In contrast, increase in advancements for developing advanced testing kits for specific type of HPV infection and owing to presence of high population base provide lucrative opportunities to the market players. .  

The outbreak of COVID-19 has disrupted workflows in the health care sector around the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. The HPV testing and Pap test industry experienced a decline in 2021 due to global economic recession led by COVID-19. In addition, the COVID-19 outbreak disrupted the supply chain of testing kits required for cervical cancer screening across various end-user industries like hospitals and pharmacies. 

However, the market is anticipated to witness recovery in 2021, and show stable growth for HPV testing and Pap test market in the coming future. This is attributed to the increase in adoption of various screening techniques for genetic women population and increasing awareness regarding cervical cancer to drive the market growth.  

Segmental Overview 

The global HPV testing and Pap test market is segmented into test type, application, location of testing and region. By test type, the market is categorized into HPV test, pap test and co-test. On the basis of application, the market is segregated into cervical cancer and vaginal cancer. On the basis of location of testing, the market is categorized into hospitals and clinics, diagnostic centers, and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).   

By test type: Depending on test type, the market is bifurcated into HPV test, pap test and co-test. The pap test segment exhibited highest HPV testing and Pap test market share in 2021, and is expected to remain dominant during the forecast period, owing to rise in adoption of this test in major countries and ability of test to detect risk of developing cervical cancer as compared to HPV test. Moreover, co-test segment is projected to register a CAGR of 8.6% during the forecast period, owing to higher percentage of cervical cancer identification as compared to HPV testing or pap test alone. 

By application: On the basis of application, the market is classified into cervical cancer & vaginal cancer. The cervical cancer segment dominated the market in 2021. This is attributed to rise in prevalence of cervical cancer cases in many countries. Moreover, the cervical cancer segment is projected to register a CAGR of 6.3% during the forecast period, owing to rise in awareness regarding cervical cancer screening.   

By location of testing: On the basis of location of testing, the market is categorized into hospitals and clinics, diagnostic centers, and others. The diagnostic center segment occupied highest share in 2021 and is expected to remain dominant during forecast period owing to high population coverage for cervical cancer screening through trained persons and precise results obtained. The others segment is projected to register highest CAGR of 6.7% owing to increase in screening through self-sampling kits as it offers privacy and remote screening.   

By region: The HPV testing and Pap test market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Region wise, North America had the highest HPV testing and Pap test market share in 2021, and is expected to maintain its lead during the forecast period, owing to increase in prevalence of cervical cancers and rise in healthcare infrastructure for cervical cancer screening. In addition, rise in no of key players manufacturing screening test kits and increase in awareness regarding screening for cervical cancer further drives the market growth in this region.  

Asia-Pacific expected to grow at the highest rate during HPV testing and Pap test market forecast. The market growth in this region is attributable to presence of key players in the region. Moreover, rise in adoption of various screening tests for cervical cancer drive the growth of the market. In addition, various countries in this region, have started population based free screening programs for cervical cancer for women aged 30 – 65 years. For instance, according to article published in National Library of Medicine 2021, stated that for elimination of cervical cancer Chinese government has launched free screening program for rural women aged 30‐’65 years which drives the growth of market. 

COMPETITION ANALYSIS 

Competitive analysis and profiles of the major players in the HPV testing and Pap test market, Abbott Laboratories, Arbor Vita Corporation, Becton, Dickinson and Company (BD), F. Hoffmann-La Roche AG, Femasys, Hologic Inc., Mylab Discovery Solutions Pvt. Ltd, Qaigen NV, Seegene Inc and Thermo Fischer Scientific Inc. are provided in this report. Major players have adopted product launch and product approval as key developmental strategies to improve the product portfolio of the HPV testing and Pap test market.   

Product approval in the market  

In July 2020, BD (Becton, Dickinson and Company), announced that it received approval for a pre-market approval (PMA) supplement from the U.S. Food and Drug Administration (FDA) for an expanded version of its BD Onclarity HPV Assay. 

 Product Launches in the market 

In June 2022, Roche today announced the launch of a human papillomavirus (HPV) self-sampling solution in countries accepting the CE mark. 

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the HPV testing and pap test market analysis from 2021 to 2031 to identify the prevailing hpv testing and pap test market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the HPV testing and pap test market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes an analysis of the regional as well as global HPV testing and Pap test industry, key players, market segments, application areas, and market growth strategies.

  HPV Testing & Pap Test Market Report Highlights

Aspects	Details
Market Size By 2031	USD 6.7 billion
Growth Rate	CAGR of 6.1%
Forecast period	2021 - 2031
Report Pages	208
By Test Type	HPV test Pap Test Co-test
By Application	Cervical Cancer Vaginal Cancer
By Location of Testing	Hospitals and clinics Diagnostic Centers Others
By Region	North America  (U.S., Canada, Mexico) Europe  (Germany, France, UK, Italy, Spain, Rest of Europe) Asia-Pacific  (Japan, China, India, Australia, South Korea, Rest of Asia-Pacific) LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players	Thermo Fisher Scientific Inc., Qaigen NV, F. Hoffmann-La Roche AG, Seegene Inc, Arbor vita corporation, Hologic Inc., Femasys Inc., Abbott Laboratories, Mylab Discovery Solutions Pvt. Ltd, Becton, Dickinson and Company

Analyst Review

Increase in demand for advanced screening for cervical cancer globally is expected to offer profitable opportunities for the expansion of the market. In addition, favorable government policies and schemes for screening test, has piqued the interest of several companies to develop advanced diagnostic test. 

Increase in cervical and vaginal cancer cases in developing regions has largely contributed in the market revenue in 2021, and is expected to maintain this trend throughout the forecast period. In addition, awareness regarding early screening to eliminate cervical cancers across globe, increase in demand of self-sampling test in many countries significantly contributes towards the revenue generation. Moreover, use of co-test for cervical cancer screening will boost the growth of market.  

Furthermore, North America is expected to witness highest growth, in terms of revenue, owing to increase in awareness towards screening of cervical and vaginal cancer and rise in government initiatives promoting research activities for development of new advanced screening test drives the market growth. Upsurge in healthcare expenditure in the emerging economies is anticipated to offer lucrative opportunities for the market expansion. However, Asia-Pacific is anticipated to witness notable growth, owing to increase in investments for manufacturing HPV testing and Pap test kits and increase in cervical cancer cases during the forecast period. 

Author Name(s) : Monika Darandale | Roshan Deshmukh

Related Tags

• Cancer Drugs
• Cancer Diagnostics
• In Vitro Diagnostics Ivd
• Diagnostic Testing
• Genomic Technologies
• Clinical Diagnostics
• Molecular Biology